Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Kathleen N. Moore(University of Oklahoma Health Sciences Center), Angeles Alvarez Secord(Duke University Health System), Melissa A. Geller(University of Minnesota), David S. Miller(The University of Texas Southwestern Medical Center), Noelle Cloven(Texas Oncology), Gini F. Fleming(University of Chicago), Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona), Masoud Azodi(Yale University), Paul DiSilvestro(Providence College), Amit M. Oza(University Health Network), Mihaela Cristea(City Of Hope National Medical Center), Jonathan S. Berek(Cancer Prevention Institute of California), John K. Chan(Sutter Health), B.J. Rimel(Cedars-Sinai Medical Center), Daniela Matei(Northwestern University), Yong Li(Tesaro (United States)), Kaiming Sun(Tesaro (United States)), Katarina Luptakova(Tesaro (United States)), Ursula A. Matulonis(Harvard University), Bradley J. Monk(University of Arizona)
The Lancet Oncology
April 1, 2019
Cited by 531

Abstract


Related Papers

No related papers found

Powered by citation graph analysis